Using antisera made against peptides corresponding to different regions of the large subunit of herpes simplex virus type 1 ribonucleotide reductase we have probed proteolytic fragments of this protein and found that at least a part of its unique Nterminal domain is not necessary for enzyme activity. This non-essential region encompasses the domain previously predicted to be composed of/~ sheets with a well buried core of hydrophobic residues. Truncated forms of the large subunit are generated in vivo and are located almost exclusively in the nucleus.
INTRODUCTION
Formation of the four deoxyribonucleotides from their corresponding ribonucleotides is the first specific step in DNA synthesis. The reaction is catalysed by the enzyme ribonucleotide reductase (EC 1.17.4.1 ; ribonucleoside-diphosphate reductase) which plays a key role in DNA metabolism. Its activity is regulated in a number of ways differing from organism to organism (for reviews see Thelander & Reichard, 1979; Lammers & Follman, 1983; Eriksson & Sj6berg, 1989; Reichard, 1988) .
The herpes simplex virus (HSV)-coded ribonucleotide reductase (RR) (Cohen, 1972; Dutia, 1983 ; Preston et al., 1984) consists of two non-identical subunits (Frame et al., 1985; Bacchetti et al., 1986; Ingemarson & Lankinen, 1987; Darling et al., 1988) termed RR1 and RR2 (Frame et al., 1985) or H1 and H2 (Cohen et al., 1985) . Sedimentation analysis of the enzyme suggests that both subunits are homodimers (Ingemarson & Lankinen, 1987) with the same basic structure as the Escherichia coli and mammalian reductases.
Chemical dissociation of the subunits leads to inactivation of the enzyme (Bacchetti et al., 1986) . Two recent independent reports have described reconstitution of enzyme activity from the free subunits. One method (Huang et al., 1988) made use of separate expression systems for the two proteins to demonstrate reconstitution of activity in vitro, and further showed that no additional HSV-encoded proteins were necessary for enzyme activity; the second (Darling et al., 1988) used two temperature-sensitive (ts) mutants, one of which produced a free functional large subunit and the other a free functional small subunit, to show reconstitution both in vivo and in vitro.
The genetic locus encoding HSV RR has been studied extensively (Anderson et al., 1981 ; McLauchlan & Clements, 1982 , 1983a Galloway et al., 1982; Galloway & Swain, 1984) . The genes for RR1 and RR2, UL39 and UL40 respectively (McGeoch et al., 1988) , encode two unspliced 3' coterminal mRNAs, which do not share any coding regions and have been sequenced for HSV-1 (Draper et al., 1982; McLauchlan & Clements, 1983a; Nikas et al., 1986) and HSV-2 (McLauchlan & Clements, 1983b; Swain & Galloway, 1986) . Both subunits are highly conserved between HSV-1 and HSV-2 and show distinct amino acid homologies with equivalent proteins from Epstein-Barr virus (Baer et al., 1984; Gibson et al., 1984) , varicellazoster virus (Davison & Scott, 1986; Nikas et al., 1986) , E. coli (Carlson et al., 1984; Sj6berg et al., 1985) , T4 bacteriophage (Sj6berg et al., 1986) , surf clam (Standart et al., 1985) , mouse (Caras et al., 1985) , vaccinia virus (Slabaugh et al., 1988) and yeast (Elledge & Davis, 1987; Hurd et al., 0000-9004 © 1989 SGM 1987 . A comparison by N ikas et al. (1986) identified 15 blocks of conserved amino acids in RR 1 and six blocks in RR2 which are thought to represent functionally important domains.
A striking feature which emerged from the work of Nikas et al. (1986) was that the RR1 subunits of both HSV-1 and HSV-2 carry a unique N-terminal domain of 311 and 318 amino acids long, respectively. This is consistent with the larger apparent Mr of the HSV RR1 (about 136K) (Preston et al., 1984) compared with that of RR1 from other species (approx. 80K to 90K).
It has been observed that in extracts of HSV-infected Vero ceils, RR1 can be degraded to a 93K form which retains enzyme activity (Ingemarson & Lankinen, 1987) . Together with the above findings, this raises the possibility that the unique N-terminal domain of HSV RR1 may be unnecessary or even irrelevant for enzyme activity. We now report the use of antisera directed against different regions of RR1 and provide the first direct evidence that at least a part of the N-terminal domain of RR1 is not needed for enzyme activity.
METHODS

Growth of cells and virus.
Vero cells and BHK-21 clone 13 cells were grown in Dulbecco's modified Eagle's medium containing 10~ (v/v) calf serum. HSV-1 strain 17 syn ÷ (Brown et al., 1973) and the derived ts mutant tsK (Marsden et al., 1976) were propagated in BHK cells (Macpherson & Stoker, 1962) .
Radioisotope labelling and SDS-PAGE. Dishes of BHK cells were infected with 20 p.f.u./cell. After 1 h the virus was removed and growth was continued in Eagle's medium containing one-fifth the normal concentration of methionine, supplemented with 2~ calf serum (labelling medium). For continuous labelling cells were grown in the presence of [3SS]methionine (Amersham); sp. act. > 600 Ci/mmol) at a concentration of 10 laCi/ml. Label was added 2 h after the virus adsorption period and cultures were harvested 16 to 20 h later. To pulse-label cells the growth medium was removed at 5 h post-infection and [3sS]methionine (100 vtCi/ml) was added in phosphatebuffered saline (PBS) with 1 ~ non-essential amino acids for the times indicated in the text. The cells were either harvested immediately (pulse) or the label was chased by washing the monolayers three times with Eagle's medium supplemented with 2 ~ calf serum, followed by further incubation in that medium. Control mock-infected cultures were treated in a similar manner except virus was omitted.
To harvest infected cells the monolayers were washed with PBS and then lysed and denatured on the plastic surface on which they were growing (Marsden et al., 1978) . SDS-PAGE of proteins was performed in 5 to 12~ gradient gels cross-linked with 5~ (w/w) N,N'-methylenebisacrylamide. The buffer system used was that of Laemmli (1970) . Gels were routinely fixed, treated with En3Hance (New England Nuclear), dried and exposed to X-ray film (XS-1 or XAR-5; Eastman Kodak) at -70 °C.
Preparation of cell extracts for Western blotting. Confluent monolayers of Vero or BHK cells in roller bottles were infected with 20 p.f.u./cell (or were mock-infected) in 40 ml of Eagle's medium containing 2~ calf serum for 16 h at 31 °C. Proteins were extracted from infected cells essentially as described by Ingemarson & Lankinen (1987) with some modifications. Briefly, cells were washed twice with PBS, detached with glass beads into PBS and collected by centrifugation. The pellets were suspended into an equal volume of the lysis buffer (20 mM-HEPES pH 7.5, 10 mM-MgC12, 2 mM-DTT) with or without addition of 1 mM-TLCK protease inhibitor (Sigma). All the buffers were kept ice-cold, The cell suspensions were frozen and stored at -70 °C until required.
As required the cell suspensions were thawed rapidly and kept on ice. The cells were disrupted either by homogenization in a glass homogenizer in the presence of TLCK, or by sonication for four 15 s periods in the absence of a protease inhibitor to permit proteolysis. Debris was removed by centrifugation at 12 000 r.p.m, for 30 min in a Sorvall SS-34 rotor at 4 °C. From one roller bottle (10 s to 2 x l0 s cells) approximately 1 ml of extract was obtained in this way with a protein concentration of 3 to 4 mg/ml as estimated by the Bradford (1976) method and specific labelling of 5 x l07 to l0 × 107 c.p.m./mg protein.
In some experiments the cell extracts to be used for Western blotting were enriched for RR1. Purified monoclonal antibody (MAb) 932 (5 mg) was coupled to 1 ml CNBr-activated Sepharose (Pharmacia) as described by the manufacturer. A total of 2 mg of labelled protein extract was added per ml of antibody-Sepharose which had been equilibrated in binding buffer (12.5 mi-Tris-HC1 pH 7.5, 2.5 mM-EDTA, 0.5~ Triton X-100, 0.25~ sodium deoxycholate, 250 mi-NaC1). The total column volume was adjusted with the binding buffer to give a 30~ (v/v) suspension of Sepharose. The suspension was rotated end-over-end in the column for 1 h at 4 °C after which the buffer containing non-bound protein was discarded. The Sepharose was washed extensively with the binding buffer and then with l0 mi-Tris-HCl pH 7-5, 1 mM-EDTA. The bound proteins were eluted with 3M-sodium thiocyanate, 0-01 M-Tris-HC1 pH 7.8, precipitated with 5~ trichloroacetic acid and dissolved in SDS-PAGE sample buffer. The resulting material was enriched 20-to 25-fold for RR1.
Western blotting. Western blots were performed essentially as described by Towbin et al. (1979) . The antisera were used in 1 : 10 or 1:20 dilutions. Horseradish peroxidase-conjugated anti-mouse immunoglobulin was used to visualize bound mouse MAbs and horseradish-conjugated Protein A was used to visualize bound rabbit antibodies.
Synthetic oligopeptides. Peptides MASRPAASSPEVY, TQTADVPTEALY and RNSQFVALMPTA were purchased from Cambridge Research Biochemicals. Peptides EGLSDPRPRLGTGTA, YPVPLELTPEN-AEAVA and KATNSGVFGGDDNIV were synthesized by continuous-flow Fmoc chemistry (reviewed by Atherton et al., 1979; Sheppard, 1983) using an LKB Biolynx peptide synthesizer. Chemicals for these syntheses were purchased from LKB Biochrom with the exception of dimethylformamide (Rathburn Chemicals), trifluoroacetic acid (Aldrich) and resin to which the first amino acid had been coupled via an acid-labile bond (Peptide and Protein Research). Peptides were synthesized both directly onto the resin and onto a branching lysine core to generate a peptide with eight identical branches (Possnett et al., 1988; Tam, 1988) using two columns of the synthesizer in series. The lysine core was synthesized (onto an alanine residue coupled to the resin) using Fmoc-lys (Fmoc) pentafluorophenyl ester (Peptide and Protein Research).
Following synthesis peptides were cleaved from the resin and side-chain protecting groups removed with 95 trifluoroacetic acid in HzO (plus 4 ~ w/v phenol for the arginine-containing peptide) using standard protocols. The Mr values of the single peptides and the polylysine core were determined by mass spectrometry (M-scan) which gave values identical to those expected. The amino acid composition of the branched peptides were determined by amino acid analysis (M-Scan) and were in agreement with expectations.
Antisera. Monoclonal antibodies 932 and 535 specific for RR1 and RR2 respectively (Ingemarson & Lankinen, 1987) were a gift from L. Thelander. Rabbit sera NI, N2 and C2 ( Fig. 1 ) were raised as previously described (Frame et al., 1985) . Peptides were coupled to the carrier protein either via an added tyrosine (Bassiri et al., 1979) or directly through the carboxy-terminal group (Kagan & Glick, 1979; Walter et al., 1980) . The branched peptides used to produce sera N3, C1 and C3 ( Fig. 1) were injected (100 gg per immunization per rabbit) without an additional hapten.
Cellfractionation. Cells were fractionated into nucleus and cytoplasm by the method of Zieve & Penman (1976) .
RESULTS
Fig. 1 is a schematic representation of the genome of HSV-1 and shows the position of UL39, the coding region of RR1 (McGeoch et al., 1988) , the boundary of the unique N-terminal domain, and the position of the six amino acid sequences against which antisera were raised. The antisera are designated N1, N2, N3, C1, C2 and C3 as indicated. Fig. 2(a) shows an autoradiograph of [3SS]methionine-labelled infected or mock-infected cell proteins after separation by SDS-PAGE and transfer to nitrocellulose membrane and Fig. 2 illustrates reactivity of various sera with the transferred polypeptides on Western blots. Lane 1 of (a) shows the infected Vero cell extract in which proteolysis of RR1 was prevented by TLCK. Lane 2 shows an infected degraded Vero cell extract which was prepared under conditions permitting proteolysis to occur. To enrich for RRl-related polypeptides, the crude extracts were first purified by immunoaffinity chromatography using M A b 932 (lanes 3 to 11). This procedure selected no detectable protein from mock-infected cells (lanes 3, 6 and 9). From infected cells extracted in the presence of T L C K the proteins which were purified were major capsid protein, RR1, RR2 and also some intermediate-sized proteins (lanes 4, 7 and 10). From cells extracted under conditions permitting proteolysis to occur no detectable RR1 w a s purified; instead several proteins of lower apparent Mr were seen (lanes 5, 8 and 11). The identity of RR1, its degradation products and that of RR2 was determined on Western blots (Fig. 2b) . The reactivities of various sera with these blotted proteins is shown in Fig. 2 (b) in which each lane number corresponds to that in Fig. 2 (a) . MAbs 932 and 535 reacted with proteins RR1 (two forms were seen here, labelled R R l a and R R l b ) , RR2 and 93K (lanes 1 and 4) and 81K (lanes 2 and 5). The other proteins visualized also with N1 and C2 antisera are M A b 932 heavy (v2A) and light (x) chains derived from the MAb 932-antibody-Sepharose column with which both Fig. 2. (a) Autoradiography of [35S]methionine-labelled proteins separated by SDS-PAGE and transferred to nitrocellulose for immunoblotting. The labelled whole infected Vero cell extracts were prepared and RR1 was immunoaffinity-purified from the extracts by MAb 932 as described in Methods. The amount of protein loaded on th e gels was 100 ktg of whole cell extract (lanes 1 and 2) or 5 ~tg of purified protein (lanes 4, 5, 7, 8, 10 and 11). Lane 1 shows the infected undegraded extract and lane 2 the infected degradedextract. A mock-infected cell extract was also subjected to the purification and, as expected, little protein was specifically bound to the column; approximately 0.2 p.g of such protein was loaded on the gel. Lanes 3, 6 and 9 are mock-infected cell samples, lanes 4, 7 and 10 are enriched infected undegraded and lanes 5, 8 and 11 are enriched infected degraded extracts. In this and subsequent figures polypeptides were separated on a 5 to 12.5% SDS-polyacrylamide gradient gel. (b) Reactivity of the transferred proteins shown in (a) with the N 1 (lanes 6, 7 and 8) and C2 (lanes 9, 10 and 11) antisera as well as the 932 and 535 MAbs (lanes 1 to 5). . All the antisera were tested against 100 p.g of whole cell extract from mock-infected (lanes 1, 5 and 9), infected (lanes 2, 6 and 10) and infected degraded (lanes 3, 7 and 11) Vero cells, where proteins were solubilized by homogenization, and lanes 4, 8 and 12 from infected degraded extracts where cells were disrupted by sonication. As controls MAb 932 and the preimmune (PI) serum for C3 were used.
anti-mouse and Protein A react. N 1 antiserum reacts with RR la but not with RR1 b or any other truncated forms of RR1 (lanes 7 and 8). In contrast the C2 antiserum reacts with not only RR1 but also the 93K (lane 10) and 81K (lane 11) polypeptides. Antiserum C2 also recognizes two other polypeptides (arrowed) which appear to be additional degradation products of RR1.
In preliminary experiments we found that the proteolytic fragments were reproducibly generated in extracts of infected BHK cells as well as infected Vero cells. The reactivities of antisera N2 and C 1 were investigated using an extract from infected BHK cells. Antiserum C2 reacted with RR 1 and the 93K and 81K fragments (lane 4) consistent with results from infected Vero cells (Fig. 2) ; antiserum N2 reacts with RR1 but none of the proteolytic fragments (Fig. 3,  lane 6) .
Antiserum N3 reacts with 136K and the 93K degradation product but not 81K (Fig. 4 , lanes 5 to 8). This serum also reacts with an 85K polypeptide which is an additional degradation component seen in some extracts and occasionally in blots probed with MAb 932 as well as C2 and C3 antisera. The asterisk indicates this protein which is here visualized by N3 antiserum. Antiserum C3 reacts with the 136K, 93K, 85K and 81K polypeptides. Fig. 5 summarizes the reactivities of the various antisera on Western blots with RR1 and the 93K and 81K degradation products.
Generation of the 93K and 81K polypeptides in vivo and their cellular localization
In the experiments described so far the 93K and 81K polypeptides were produced in vitro following the extraction of the RR enzyme. To investigate whether such products might accumulate in vivo we took advantage of the observation that RR1 (as well as the immediate early polypeptides of apparent Mr values 175K, 110K, 68K, 63K and 12K) are overproduced in cells infected with tsK at the non-permissive temperature (Preston, 1979) . Thus cells infected at 38 °C with tsK provide a ready source of RR1. Such cells were pulse-labelled for 30 min at 6 h post-infection. During subsequent chase two polypeptides accumulated (Fig. 6a, arrowed) ; tryptic peptide fingerprinting of the 136K polypeptide and these two new polypeptides established that the new ones were derived from the 136K polypeptide (data not shown). To test the possibility that these in vivo generated polypeptides corresponded to the in vitro generated 93K and 81K fragments described by Ingemarson & Lankinen (1987) , polypeptides from cells infected with tsK at non-permissive temperature were separated by SDS-PAGE, transferred to a nitrocellulose membrane and probed with MAb 932. Polypeptides of Mr 136K and the two arrowed polypeptides were detected by the antibody. The arrowed polypeptides had the same mobilities in SDS-PAGE as the 93K and 81K proteins respectively, thereby confirming that the polypeptides in question were equivalent (data not shown). Two additional polypeptides accumulate during the pulse and the chase (apparent Mr values 28K and 26K), but are not relevant here and will be discussed elsewhere.
To determine the cellular location of the 93K and 81K fragments, cells infected with tsK at 38 °C were pulse-labelled with [35S]methionine at 5 h post-absorption for 30 min, either harvested immediately or after the label had been chased for 18 h, separated into nuclear and cytoplasmic fractions, and then subjected to SDS-PAGE. Fig. 6 (b) shows that the breakdown products accumulate almost exclusively in the nucleus.
DISCUSSION
A previous study showed that RR1 breaks down to several species of apparent Mr 110K, 93K and 81K of which at least the 93K was enzymically active (Ingemarson & Lankinen, 1987) . We have now used antisera directed against different regions of RRI to investigate the primary structure of this enzymically active 93K species and provide the first evidence that at least part of the N-terminal domain of HSV RR1 protein is not needed for ribonucleotide reduction.
The analysis by Nikas et al. (1986) predicted that the N-terminal domain of RR1 consisted of two distinct similar sized regions divided by a short stretch of prolines. The first (amino acids 1 to 149) was predicted to form a domain of fl-sheets with a well buried core of hydrophobic residuesl Since antiserum N2 which does not react with the 93K species is directed to a sequence just at the end of this region our results demonstrate that this N-terminal region is not necessary for enzyme activity. The enzymically active 93K species must contain all or almost all the carboxy-terminal region since it reacts with sera C1, C2 and C3. Serum C3 is directed to an epitope within amino acids 1117 to 1131 of the 1137 amino acid RR1; as an epitope can be as small as three amino acids we are not in a position to say for certain whether the C-terminal 17 amino acids are present in the 100K polypeptide. As N3 reacts with the 93K species the cleavage site for formation of the 93K protein must lie between the amino acids recognized by antisera N2 (140)and N3 (308), so its amino terminus minimally extends to amino acid 309.
The cleavage site which generates the 81K species must lie between the amino acids recognized by antisera N3 (297 to 311) and C1 (312 to 327). The 81K species contains probably all the carboxy region since it reacts with sera C1, C2 and C3. Although it is clearly of importance to establish whether the 81K species is enzymicaUy active, this has not yet been possible. Formation of this protein in extracts lacking 93K is always accompanied by degradation of RR2 and hence the loss of enzyme activity could not be unambiguously linked to loss of one or the other. In principle it should be possible to purify the 81K species and test whether it can complement the free small subunit to produce enzyme activity (Darling et al., 1988) . We have not yet succeeded in doing this. The possibility that the 81K polypeptide cannot complement the small subunit to give an active enzyme cannot be excluded.
In vitro the 93K proteolysis fragment appears before the 81K fragment (Ingemarson & Lankinen, 1987) . We deduce that the junction of the unique N terminus and the conserved part of the protein is normally protected against proteolytic cleavage but becomes exposed after the protein has been cleaved to the 93K species. Sedimentation studies by Ingemarson & Lankinen (1987) showed that the 93K and 81K proteolytic fragments remain associated in the RR complex and together with our results this implies that covalent linkage of the unique Nterminal domain is not necessary for the structural integrity of the RR complex.
The observed proteolysis of RR1 might be expected to generate a detectable N-terminal fragment, however none was reproducibly observed (Fig. 3 and 4 ) though occasionally we have seen a heterogeneous band of about 35K (data not shown). We suspect that the cleaved Nterminal fragment is unstable and rapidly degraded to very small fragments. The role if any of the N-terminus of HSV-1 RR1 for ribonucleotide reduction is not understood. Whether any of the enzyme's kinetic properties are influenced by the domain is not known and will require purification to homogeneity of native and truncated RR1. Perhaps this N-terminal domain plays some other role in virus replication or latency.
Proteolysis of RR1 into the 93K and 81K species can take place in vivo (Fig. 6 ). This proteolysis is blocked by the protease inhibitor TPCK and does not take place in isolated nuclei (data not shown). In contrast with intact RR 1, which is found in both nucleus and cytoplasm, the truncated species are localized almost exclusively in the nucleus (Fig. 6) . One straightforward interpretation of the data is that RR1 which is translocated into the nucleus is degraded by proteolytic activities which are dependent on cell integrity or non-nuclear factors. Another possibility is that degraded forms of RR1 are efficiently translocated to the nucleus. Indeed, the C-terminal part of RR1 has several lysine-and arginine-containing regions which are characteristic of nuclear localization signals (Dingwall & Laskey, 1986 ), e.g. the basic motif RRFK at amino acids 1047 to 1050. There is also the possibility, which we consider unlikely, that the truncated forms are preferentially localized in traces of cytoplasmic material still adhering to the nuclear membrane after cellular fractionation.
The nonapeptide YAGAVVNDL which corresponds to the carboxyl terminus of RR2 specifically inhibits virus RR activity (Dutia et al., 1986; Cohen et al., 1986) . The enzyme has been shown to be a determinant of the pathogenicity of the virus in mice suggesting that it is a valid antiviral target (Cameron et al., 1988) . Paradis et al. (1988) showed that the nonapeptide bound not only to intact RR1 but also to proteins with apparent Mr values of 95K and 85K. These appear to be the two stable degradation products of RR1 equivalent to our 93K and 81K fragments which were estimated by Frame and co-workers (1985) to have apparent Mr values of 100K and 90K (in 5 ~ to 12.5 ~ gradient gels). We conclude that the nonapeptide interacts with the conserved carboxy 826 amino acids of RR1. This conclusion has important implications for the design of an antiviral agent based on the inhibitory nonapeptide YAGAVVNDL. One rational approach to facilitate the design of such an agent is to purify and crystallize RR1 and to obtain its three-dimensional structure by X-ray diffraction so as to visualize how the nonapeptide interacts with it. We suggest that it would be sufficient to do this with only the conserved carboxy region of RR1 -a more limited goal which should be more readily attainable.
